Meridian Bioscience Past Earnings Performance
Past criteria checks 1/6
Meridian Bioscience has been growing earnings at an average annual rate of 25.3%, while the Medical Equipment industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 13% per year. Meridian Bioscience's return on equity is 11.5%, and it has net margins of 12.7%.
Key information
25.3%
Earnings growth rate
24.7%
EPS growth rate
| Medical Equipment Industry Growth | 8.9% |
| Revenue growth rate | 13.0% |
| Return on equity | 11.5% |
| Net Margin | 12.7% |
| Last Earnings Update | 30 Sep 2022 |
Recent past performance updates
Recent updates
Meridian Bioscience Non-GAAP EPS of $0.16 misses by $0.01, revenue of $67.8M beats by $1M
Aug 05Meridian Bioscience: High-Probability Merger Arbitrage
Jul 26Meridian Bioscience downgraded at William Blair on $1.53B acquisition
Jul 07Meridian Bioscience (NASDAQ:VIVO) Has A Pretty Healthy Balance Sheet
Jun 27
Meridian Bioscience: Correctly Valued
Jun 26Many Would Be Envious Of Meridian Bioscience's (NASDAQ:VIVO) Excellent Returns On Capital
Jun 09Meridian Bioscience: Deceptively Priced
Mar 14Meridian Bioscience (NASDAQ:VIVO) Looks To Prolong Its Impressive Returns
Feb 03These 4 Measures Indicate That Meridian Bioscience (NASDAQ:VIVO) Is Using Debt Safely
Jul 19If The COVID-19 Delta Variant Spreads This Fall, Meridian Is Still A Buy
Jul 08Meridian Bioscience (NASDAQ:VIVO) Might Become A Compounding Machine
May 10Meridian Bioscience, Inc. 2021 Q2 - Results - Earnings Call Presentation
May 08Meridian Bioscience (NASDAQ:VIVO) Seems To Use Debt Rather Sparingly
Mar 31Have Insiders Been Buying Meridian Bioscience, Inc. (NASDAQ:VIVO) Shares?
Mar 11Investors Who Bought Meridian Bioscience (NASDAQ:VIVO) Shares A Year Ago Are Now Up 185%
Feb 24Need To Know: Analysts Are Much More Bullish On Meridian Bioscience, Inc. (NASDAQ:VIVO) Revenues
Feb 09
Meridian expands production capacity for COVID-19 tests with NIH funding
Feb 03Should We Be Excited About The Trends Of Returns At Meridian Bioscience (NASDAQ:VIVO)?
Jan 27Revenue & Expenses Breakdown
How Meridian Bioscience makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 22 | 333 | 42 | 88 | 24 |
| 30 Jun 22 | 344 | 43 | 90 | 24 |
| 31 Mar 22 | 339 | 62 | 86 | 24 |
| 31 Dec 21 | 313 | 60 | 80 | 24 |
| 30 Sep 21 | 318 | 71 | 76 | 24 |
| 30 Jun 21 | 306 | 71 | 76 | 25 |
| 31 Mar 21 | 327 | 87 | 76 | 25 |
| 31 Dec 20 | 299 | 70 | 74 | 25 |
| 30 Sep 20 | 254 | 46 | 71 | 24 |
| 30 Jun 20 | 240 | 44 | 68 | 22 |
| 31 Mar 20 | 204 | 21 | 64 | 20 |
| 31 Dec 19 | 197 | 19 | 61 | 19 |
| 30 Sep 19 | 201 | 24 | 62 | 18 |
| 30 Jun 19 | 203 | 26 | 62 | 16 |
| 31 Mar 19 | 207 | 27 | 64 | 16 |
| 31 Dec 18 | 213 | 26 | 68 | 16 |
| 30 Sep 18 | 214 | 24 | 70 | 17 |
| 30 Jun 18 | 210 | 24 | 69 | 18 |
| 31 Mar 18 | 209 | 18 | 68 | 17 |
| 31 Dec 17 | 206 | 22 | 66 | 17 |
| 30 Sep 17 | 201 | 22 | 63 | 16 |
| 30 Jun 17 | 198 | 21 | 63 | 15 |
| 31 Mar 17 | 199 | 30 | 63 | 15 |
| 31 Dec 16 | 195 | 30 | 61 | 14 |
| 30 Sep 16 | 196 | 32 | 59 | 14 |
| 30 Jun 16 | 195 | 35 | 58 | 13 |
| 31 Mar 16 | 192 | 36 | 55 | 13 |
Quality Earnings: VIVO has a large one-off loss of $21.2M impacting its last 12 months of financial results to 30th September, 2022.
Growing Profit Margin: VIVO's current net profit margins (12.7%) are lower than last year (22.5%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: VIVO's earnings have grown significantly by 25.3% per year over the past 5 years.
Accelerating Growth: VIVO's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: VIVO had negative earnings growth (-40.5%) over the past year, making it difficult to compare to the Medical Equipment industry average (3.7%).
Return on Equity
High ROE: VIVO's Return on Equity (11.5%) is considered low.